Accounts Receivable, after Allowance for Credit Loss, Current of Grace Therapeutics, Inc. from 31 Mar 2019 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Grace Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Mar 2019 to 30 Jun 2024.
  • Grace Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Jun 2024 was $398,000, a 52% decline year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Grace Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $398,000 -$439,000 -52% 30 Jun 2024 10-Q 09 Aug 2024 2024 Q1
Q1 2024 $722,000 -$80,000 -10% 31 Mar 2024 10-Q 09 Aug 2024 2024 Q1
Q4 2023 $959,000 31 Dec 2023 10-Q 12 Feb 2024 2024 Q3
Q3 2023 $837,000 30 Sep 2023 10-Q 13 Nov 2023 2024 Q2
Q2 2023 $837,000 30 Jun 2023 10-Q 11 Aug 2023 2023 Q1
Q1 2023 $802,000 +$254,000 +46% 31 Mar 2023 10-K 21 Jun 2024 2024 FY
Q1 2022 $548,000 +$18,000 +3.4% 31 Mar 2022 10-K 23 Jun 2023 2023 FY
Q1 2021 $530,000 -$16,000 -2.9% 31 Mar 2021 10-K 21 Jun 2022 2022 FY
Q1 2020 $546,000 -$643,000 -54% 31 Mar 2020 10-K 22 Jun 2021 2021 FY
Q1 2019 $1,189,000 31 Mar 2019 10-K 29 Jun 2020 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.